Industries > Pharma > Ophthalmic Drugs Market Report to 2030

Ophthalmic Drugs Market Report to 2030

Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 26 November 2020
PAGES: 696
PRODUCT CODE: PHA1022
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1022 Categories: , Tags: , ,

• Discover the impact of COVID-19 and the subsequent recession/ economic recovery on the Ophthalmic drugs market.
• Realize which global markets are set to be most profitable over the next 10 years for ophthalmic drugs – will the US still dominate this market?
• Unearth which of the new ophthalmic medications (treating glaucoma, waterfall, diabetic retinopathy, and other ophthalmic problems) – along with novel medications – will be the most effective and biggest sellers over the next decade.
• Establish which of the new mergers, acquisitions and collaborations are changing competitive dynamics today.

Which are your competitors and key players doing this year? This report will tell you.

The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key opportunities – what are they and how can you benefit? This report will tell you.

With product approvals over the next decade set to be a key issue facing all competitors in the market – you must discover the essential strategies being implemented by key market players between 2015 and Jan 2021.

Includes crucial sales predictions for the global ophthalmic drugs market and submarkets along with breakdown by region, country and the impact of COVID-19 on those markets. Also included is key segmentation analysis of the ophthalmic drugs market, with forecasts across disease type, infections and distribution channels. Products are forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

To access the data contained in this document please email contactus@visiongain.com

Leading companies and the potential for market growth
As per Visiongain analysis, global ophthalmic drugs market is estimated to be valued at US$xx in 2021 and is projected to reach at a market value of US$xx by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Why You Should Buy Visiongain Report only?
The report study aims to explore the market drivers, restraints and also market opportunities facing dermatological drugs product stakeholders in different geographic areas. Also, it identifies trends, gaps, and opportunities in each micro market segment. Finally, this report identifies the major stakeholders, product portfolios, and recent developments in order to draw a competitive landscape for players in this market.

CTA

This unique limited edition report also includes exclusive analysis by

By Indication
• Dry Eye
• Glaucoma Drugs
• Retinal Disorders Drugs
• Allergic, Inflammatory & Infective Drugs
• Others

By Type
• Prescription Drugs
• OTC Drugs

By Distribution Channel
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies

By Region

• North America
– U.S.
– Canada

• Europe
– Germany
– France
– United Kingdom
– Italy
– Spain
– Russia
– Poland
– Rest of Europe

• Asia Pacific
– China
– Japan
– India
– Australia
– South Korea
– Rest of Asia Pacific

• Latin America
– Brazil
– Mexico
– Rest of Latin America

• Middle East & Africa
– Saudi Arabia
– South Africa
– UAE
– Rest of Middle East & Africa

Ophthalmic Drugs Market Report 2020-2030
Need industry data? Please contact us today.

This report includes revenue forecasts over the next decade for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs 5
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company’s activities and outlook
• Ophthalmic drugs revenue forecasts

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities – assess innovation, trends and possibilities

What is happening in the R&D pipeline for ophthalmic treatments? You see developmental trends, gaining insight into each phase of the ophthalmology R&D pipeline for:
• Dry eye drugs
• Glaucoma drugs
• Allergic, infective and inflammatory drugs
• Retinal disorder drugs
• Other progress in ophthalmology

With analysis of key ophthalmic drugs market players – such as – Novartis, Regeneron, Allergan, Roche, Santen Pharmaceutical Co., Bayer, Pfizer, Senju Pharmaceutical Company Ltd (Senju), Bausch Health Companies Inc., Akorn, Inc., Sun Pharmaceutical Industries Ltd., Aerie Pharmaceuticals Inc, Biogen

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Ophthalmic Drugs Market Report to 2030: Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Report to 2030


Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Report to 2030


Latest Pharma news

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

READ

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

READ

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

READ

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

READ

Categories